

1 Title: The burden of isolation to the individual: a comparison between isolation for

2 COVID-19 and for other influenza-like illnesses in Japan

3 Running title: Difference in burden of isolation between COVID-19 and ILIs

4

5 Shinya Tsuzuki, MD, MSc<sup>1,2,3\*</sup>; Norio Ohmagari, MD, PhD<sup>1,3</sup>; Philippe Beutels, PhD<sup>2</sup>

6 <sup>1</sup> AMR Clinical Reference Center, National Center for Global Health and Medicine,

7 Tokyo, Japan

8 <sup>2</sup> Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium

9 <sup>3</sup> Disease Control and Prevention Center, National Center for Global Health and

10 Medicine, Tokyo, Japan

11

12 \*Corresponding author: Shinya Tsuzuki, MD, MSc

13 National Center for Global Health and Medicine

14 1-21-1 Toyama, Shinjuku-ku, Tokyo 162-8655, Japan

15 Tel: +81(0)3-3202-7181

16 Email: [stsuzuki@hosp.ncgm.go.jp](mailto:stsuzuki@hosp.ncgm.go.jp)

17

## 18    **Abstract**

19    At present, there is scarce evidence about how much burden the isolation of COVID-19  
20    patients is. We aimed to assess the differences between COVID-19 and other influenza  
21    like illnesses in disease burden brought by isolation. We conducted an online  
22    questionnaire survey of 302 people who had COVID-19 or other influenza-like illnesses  
23    (ILIs) and compared the burden of isolation due to sickness with one-to-one propensity  
24    score matching. The primary outcomes are the duration and productivity losses of  
25    isolation, the secondary outcome is quality of life (QOL) valuation on the day of the  
26    survey. Acute symptoms of outpatient COVID-19 and other ILIs lasted 17 (interquartile  
27    range [IQR] 9-32) and 7 (IQR 4-10) days, respectively. The length of isolation due to  
28    COVID-19 was 18 (IQR 10-33) days and that due to other ILIs was 7 (IQR 4-11) days,  
29    respectively. The monetary productivity loss of isolation due to COVID-19 was 1424.3  
30    (IQR 825.6-2545.5) USD and that due to other ILIs was 606.1 (IQR 297.0-1090.9) USD,  
31    respectively. QOL at the time of the survey was lower in the COVID-19 group than in  
32    the “other ILIs” group (0.89 and 0.96,  $p = 0.001$ ). COVID-19 infection imposes a  
33    substantial disease burden, even in patients with non-severe disease. This burden is  
34    larger for COVID-19 than other ILIs, mainly because the required isolation period is  
35    longer.

36

37   **Keywords:** COVID-19; disease burden; Quality of life; isolation

38

39   **Word count:** 2038

40

41

42

## 43 **Acknowledgment**

44 We thank all the people who participated in our survey.

45

## 46 **Author contributions**

47 Shinya Tsuzuki: Conceptualization, Funding Acquisition, Data Curation, Formal

48 Analysis, Methodology, Visualization, Project Administration, Original Draft

49 Preparation. Norio Ohmagari: Funding Acquisition, Project Administration, Supervision,

50 Review and Editing. Philippe Beutels: Conceptualization, Methodology, Supervision,

51 Project Administration, Review & Editing.

52

## 53 **Data availability**

54 The data that support the findings of this study are available upon request to the

55 corresponding author. The data are not publicly available due to privacy or ethical

56 restrictions.

57

## 58 **Funding**

59 This research was funded by JSPS KAKENHI [Grant number 18K17369], a grant for

60 the National Center for Global Health and Medicine [20A05] and the Health and Labor

61 Sciences Research Grant, “Research for risk assessment and implementation of crisis  
62 management functions for emerging and re-emerging infectious diseases”. PB  
63 acknowledges support from the Epipose project from the European Union's SC1-  
64 PHE-CORONAVIRUS-2020 programme, project number 101003688, during the  
65 conduct of the study.

66

#### 67 **Conflict of interest**

68 PB reports previous unrelated grants from Pfizer, GSK, and the European Commission  
69 IMI. The other authors declare no conflicts.

70

#### 71 **Ethics approval**

72 This study was reviewed and approved by the Ethics Committee of the Center Hospital  
73 of the NCGM (NCGM-G-004001-01).

74

#### 75 **Patient consent**

76 Written informed consent was obtained by each participant before starting the survey  
77 through an electronic form.

78

79     **Permission to reproduce material from other sources**

80     Not applicable.

81

## 82 **Introduction**

83 Coronavirus disease 2019 (COVID-19) caused by the SARS-CoV-2 virus, has become a  
84 global health threat [1–3]. More than half a year after the roll-out of highly effective  
85 vaccines against COVID-19, the pandemic remains difficult to control [4].

86 COVID-19 can be regarded as one of the influenza-like illnesses (ILIs) because it  
87 causes upper respiratory symptoms like seasonal influenza and its severity is mild in  
88 most cases [5–7]. However, there are several distinctive characteristics which  
89 differentiate COVID-19 from other ILIs.

90 First, COVID-19 is more likely to result in severe illness and death than other ILIs  
91 do. Previous studies suggested that the infection-fatality rate of COVID-19 was about  
92 ten times higher than that of seasonal influenza [5,8]. Although patients often recover  
93 with only mild symptoms, COVID-19 infection should be another important cause of  
94 excess death [9].

95 Second, the transmission dynamics of COVID-19 is quite different from other ILIs,  
96 in that pre- and asymptomatic transmission is more common than for other ILIs [10–12].  
97 Additionally, both incubation period and infectious period of COVID-19 were regarded  
98 as longer than those of other ILIs [13,14]. These facts suggest that COVID-19 required  
99 a longer duration of isolation as a countermeasure in order to slow down its spread.

100 Presumably, we need to strengthen our isolation policy in order to prevent further

101 spreading of COVID-19 due to the reasons mentioned above. However, at the same time,  
102 we have to consider the societal burden of such intervention including productivity loss  
103 because its appropriate duration should be determined by a kind of trade-off between  
104 disease prevention effect and societal loss.

105 At the early stage of the pandemic, the Japanese government determined the  
106 duration of isolation for COVID-19 patients as two weeks [15], following the  
107 recommendation published by World Health Organization (WHO), Centers for Disease  
108 Control and Prevention (CDC) and other organizations [16–18]. This recommendation  
109 was updated as “10 days after symptom onset, plus at least 3 additional days without  
110 symptoms” in June 2020 [15], based on the updated recommendation published by  
111 WHO and other organizations [16–18].

112 However, these recommendations were defined based on clinical insights. It would  
113 be relevant to try and define the duration of isolation with both clinical, economic and  
114 societal aspects taken into consideration because such long duration of isolation may  
115 present a substantial burden for the patients.

116 At present, there is scarce evidence about how much burden the isolation of  
117 COVID-19 patients is. The main objective of the present study is to estimate its burden  
118 from a societal perspective.



119

## 120 **Methods**

### 121 **Settings**

122 We conducted an online questionnaire survey of 302 people who had COVID-19 or  
123 other influenza-like illnesses (ILIs) between 1<sup>st</sup> October 2019 and 28<sup>th</sup> February 2021.

124 The participants were voluntarily and randomly recruited from registrants of NEO  
125 MARKETING INC, a Japanese marketing research company. The participants were  
126 asked to provide information on the latest episode of isolation due to having ILIs during  
127 the study period and stratified them into (a) COVID-19 group and (b) other ILIs group.

128 We defined ILIs as these diseases diagnosed by physicians; COVID-19, seasonal  
129 influenza, adenovirus infection, respiratory syncytial virus (RSV) infection, hand, foot  
130 and mouth disease, pertussis, and other common colds. We did not use the definition of  
131 ILI [19] because asymptomatic infection is common in COVID-19 and other ILIs, in  
132 which case not symptoms, but diagnoses provide the rationale for isolation. The  
133 responders had to be at least 20 years old. Informed consent was given before the start  
134 of the survey.

135

### 136 **Statistical analysis**

137 We collected data on sex, age, number of household members, education level,

138 household and individual income, duration of symptoms and isolation, and Quality of  
139 Life (QOL) at the time of questionnaire survey. As for QOL, we used the 15-D  
140 questionnaire [20] to estimate QOL value at the time the survey was conducted.  
141 Categorical variables were presented as absolute number and percentage, continuous  
142 variables as median and interquartile range (IQR).

143 We compared the COVID-19 group with the “other ILIs” group. The primary  
144 outcome is duration and productivity loss of isolation evaluated as monetary value; the  
145 secondary outcome is QOL value. We compared the outcomes between two groups  
146 using Mann-Whitney U test with one-to-one, nearest neighbour propensity score  
147 matching (caliper = 0.2) [21]. Age, sex, education level and presence of underlying  
148 medical conditions were adjusted. Monetary value of productivity loss was calculated  
149 by multiplication of duration (days) and wage of each participant (per day equivalent).  
150 We transformed Japanese Yen (JPY) to USD as 110 JPY = 1 USD, according to the  
151 exchange rate in 2021. The QOL values were compared after excluding participants  
152 who presented any symptoms at the time of questionnaire survey. Additionally, we  
153 compared QOL values between participants who presented any symptoms due to  
154 COVID-19 and those do not.

155 Two-sided  $p$  values of  $< 0.05$  were considered to show statistical significance.

156 All analyses were conducted by R, version 4.0.5.[22]

157

## 158 **Ethics approval**

159 This study was approved by the Ethics Committee of National Center for Global Health

160 and Medicine (NCGM-G-004001-01).

161

## 162     **Results**

163     Table 1 shows the demographic characteristics of participants. 138 were classified into  
164     COVID-19 group and 164 were other ILIs group. The basic characteristics of two  
165     groups were similar. The median duration of symptoms and isolation for other ILIs  
166     group were 7 days, while those for COVID-19 group were 15.5 and 17.0 days.

167

168     (Table 1)

169

170             Table 2 describes the details of data after propensity score matching.  
171     Standardized mean difference (SMD) larger than 0.1 was regarded as significant  
172     imbalance.

173

174     (Table 2)

175

176             Table 3 shows the outcome comparison between the COVID-19 group and the  
177     “other ILIs” group. The COVID-19 group showed longer duration of symptoms (18  
178     days versus 7 days) and isolation (16 days versus 7 days). Productivity loss of isolation  
179     due to COVID-19 was greater than that due to other ILIs (1424.3 USD and 606.1 USD,

180 respectively). The QOL value of COVID-19 group was lower than that of other ILIs

181 group (0.96 and 0.89, respectively).

182

183 (Table 3)

184

185 Figure 1 shows the probability density curve of duration of symptoms and isolation,

186 productivity loss, and Quality of Life at the day of questionnaire survey.

187

188 (Figure 1)

189

190

## 191 **Discussion**

192 We showed the difference between COVID-19 and other ILIs in relation to the  
193 individual QOL and economic impact of isolation. As expected, COVID-19 imposes us  
194 heavier burden on our society than other ILIs such as seasonal influenza do in various  
195 aspects.

196 First, the longer duration of isolation brings us greater absenteeism. It is noteworthy  
197 that the median duration of isolation (16 days by the data after propensity score  
198 matching) was longer than 14 days. As described above, its duration in Japan was  
199 determined as 14 days at the early stage of the pandemic and changed to 10 days later  
200 by Ministry of Health, Labour and Welfare (MHLW) [15]. Japanese government also  
201 adopted the condition defined by WHO [16] that “plus at least 3 additional days without  
202 symptoms (including without fever and without respiratory symptoms)” then longer  
203 duration of symptoms bring us longer duration of isolation.

204 As for other ILIs group, the most frequent diagnosis was seasonal influenza (74.4%).  
205 It was probably due to the isolation policy specific to Japan [23]. Not MHLW but  
206 Ministry of Education, Culture, Sports, Science and Technology defined the isolation  
207 period due to seasonal influenza for school children based on School Health and Safety  
208 Act [24]. This law defines five-days isolation period for seasonal influenza with the day

209 of symptom onset as day 0. It is a main cause of comparatively long isolation period for  
210 seasonal influenza in Japan [23]. Therefore, the burden caused by isolation due to  
211 seasonal influenza in Japan seems heavier than that in other countries, nevertheless, that  
212 caused by COVID-19 imposes a heavier burden.

213 As a result of longer duration of isolation, its productivity loss became larger in  
214 COVID-19 group than in other ILIs group. In addition, our results showed the  
215 productivity loss from patients' perspective. If we consider societal perspective,  
216 productivity losses caused by other aspects might be another burden to our society. For  
217 instance, different from other ILIs, COVID-19 patients were often isolated (in case the  
218 patients have no risk factors of severe diseases and their cohabitants have any risk  
219 factors)[15] at not their own home but some hotels. Although their accommodation fee  
220 and healthcare professional personnel costs are covered by the government, the  
221 quantitative evaluation of these costs are not available.

222 QOL value is another point to be discussed. Even after we adjust participants'  
223 background of two groups, there were significant differences in QOL value at the day of  
224 questionnaire survey between COVID-19 group and other ILIs group (0.89 and 0.96,  
225 respectively). This result might suggest that, even if patients were not aware of its  
226 symptoms, COVID-19 had long-term effect on their health status.

227 So-called “long COVID” or “post COVID syndrome” is not fully defined [25,26],  
 228 however, one of the phenomena specific to COVID-19 compared with other ILIs and it  
 229 will bring us further additional burden on our society. In our survey, more than a half  
 230 (70/138, 50.7%) of participants who had COVID-19 infection answered that their  
 231 symptom(s) lasts more than four weeks. Conversely, only 13 out of 164 (7.9%) in other  
 232 ILIs group showed the duration of symptoms longer than four weeks. The proportion of  
 233 patients who reported “long COVID” varies between studies [27,28], and our result  
 234 (50.7%) is not substantially different from these findings. Considering this, even after  
 235 its acute phase, COVID-19 may continue to have a negative impact on QOL and  
 236 productivity, more frequently and longer than for other ILIs.

237 Our study includes several limitations. First, as our data were based on an online  
 238 survey, it requires participants to have basic internet literacy. That is, participants of our  
 239 survey might have more interest in their health status and better knowledge of basic  
 240 computational skill than the general Japanese population do.

241 Second, as already discussed in this section, productivity loss was evaluated only  
 242 from participants’ viewpoint, and no data are available about its societal perspective  
 243 (accommodation fee, healthcare professional personnel, etc.). Third, QOL was assessed  
 244 at the day of questionnaire survey and not assessed at the time they had symptoms due



245 to COVID-19 or other ILIs because 15-D questionnaire does not set any recall period.  
246 More precise quantitative evaluation of productivity loss and health-related QOL will be  
247 a future challenge.

248 In conclusion, our results showed that COVID-19 imposes heavier burden on us  
249 than other ILIs do, not only its symptoms but also productivity loss due to its longer  
250 duration of isolation. These findings will be helpful for healthcare policy makers to  
251 determine the appropriate duration of isolation. “long COVID” might be a common  
252 phenomenon which bring us an additional burden, then quantitative evaluation of the  
253 burden of “long COVID” would be one of future challenges as well as more precise  
254 assessment of productivity loss and QOL value.  
255

256

257

## References

- 258 1. **Guan W, et al.** Clinical Characteristics of Coronavirus Disease 2019 in China. *New*  
259 *England Journal of Medicine* 2020; **382**: 1708–1720.
- 260 2. **Huang C, et al.** Clinical features of patients infected with 2019 novel coronavirus  
261 in Wuhan, China. *The Lancet* 2020; **395**: 497–506.
- 262 3. **Chen N, et al.** Epidemiological and clinical characteristics of 99 cases of 2019  
263 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *The Lancet*  
264 2020; **395**: 507–513.
- 265 4. *WHO Coronavirus (COVID-19) Dashboard*. (<https://covid19.who.int>). Accessed 4  
266 July 2021.
- 267 5. **Pastor-Barriuso R, et al.** Infection fatality risk for SARS-CoV-2 in community  
268 dwelling population of Spain: nationwide seroepidemiological study. *BMJ (Clinical*  
269 *research ed.)* 2020; **371**: m4509.
- 270 6. **Tian S, et al.** Characteristics of COVID-19 infection in Beijing. *Journal of Infection*  
271 2020; Published online: February 2020.doi:10.1016/j.jinf.2020.02.018.
- 272 7. **Matsunaga N, et al.** Clinical epidemiology of hospitalized patients with COVID-19  
273 in Japan: Report of the COVID-19 REGISTRY JAPAN. *Clinical infectious*  
274 *diseases* □: *an official publication of the Infectious Diseases Society of America*  
275 2020; Published online: September 2020.doi:10.1093/cid/ciaa1470.
- 276 8. **van Asten L, et al.** Excess Deaths during Influenza and Coronavirus Disease and  
277 Infection-Fatality Rate for Severe Acute Respiratory Syndrome Coronavirus 2, the  
278 Netherlands. *Emerging Infectious Diseases* 2021; **27**: 411–420.
- 279 9. **Vestergaard LS, et al.** Excess all-cause mortality during the COVID-19 pandemic  
280 in Europe – preliminary pooled estimates from the EuroMOMO network, March to  
281 April 2020. *Eurosurveillance* European Centre for Disease Prevention and Control,  
282 2020; **25**: 2001214.
- 283 10. **Byambasuren O, et al.** Estimating the extent of asymptomatic COVID-19 and its

- 284 potential for community transmission: Systematic review and meta-analysis.  
285 *Official Journal of the Association of Medical Microbiology and Infectious Disease*  
286 Canada University of Toronto Press, 2020; **5**: 223–234.
- 287 11. **Bai Y, et al.** Presumed Asymptomatic Carrier Transmission of COVID-19. *JAMA*  
288 2020; Published online: 21 February 2020.doi:10.1001/jama.2020.2565.
- 289 12. **Ganyani T, et al.** Estimating the generation interval for coronavirus disease  
290 (COVID-19) based on symptom onset data, March 2020. *Eurosurveillance*  
291 European Centre for Disease Prevention and Control, 2020; **25**: 2000257.
- 292 13. **Backer JA, Klinkenberg D, Wallinga J.** Incubation period of 2019 novel  
293 coronavirus (2019-nCoV) infections among travellers from Wuhan, China, 20–28  
294 January 2020. *Eurosurveillance* European Centre for Disease Prevention and  
295 Control, 2020; **25**: 2000062.
- 296 14. **Chun JY, Baek G, Kim Y.** Transmission onset distribution of COVID-19.  
297 *International journal of infectious diseases: IJID: official publication of the*  
298 *International Society for Infectious Diseases* 2020; **99**: 403–407.
- 299 15. **Ministry of Health Labour and Welfare Japan.** *List of information for local*  
300 *authorities and healthcare facilities (administrative notices, etc.) (novel coronavirus*  
301 *infections)* 2020.  
302 ([https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/0000121431\\_00212.html](https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/0000121431_00212.html)).  
303 Accessed 6 July 2021.
- 304 16. **World Health Organization.** *Criteria for releasing COVID-19 patients from*  
305 *isolation.*  
306 ([https://www.who.int/news-room/commentaries/detail/criteria-for-releasing-covid-1](https://www.who.int/news-room/commentaries/detail/criteria-for-releasing-covid-19-patients-from-isolation)  
307 [9-patients-from-isolation](https://www.who.int/news-room/commentaries/detail/criteria-for-releasing-covid-19-patients-from-isolation)). Accessed 6 July 2021.
- 308 17. **Centers for Disease Control and Prevention.** *Interim Guidance on Ending*  
309 *Isolation and Precautions for Adults with COVID-19.* Centers for Disease Control  
310 and Prevention.  
311 2020(<https://www.cdc.gov/coronavirus/2019-ncov/hcp/duration-isolation.html>).  
312 Accessed 7 July 2021.
- 313 18. **European Centre for Disease Prevention and Control.** *Guidance for discharge*  
314 *and ending of isolation of people with COVID-19.*

- 2020(<https://www.ecdc.europa.eu/en/publications-data/covid-19-guidance-discharge-and-ending-isolation>). Accessed 8 July 2021.
19. **WHO**. *WHO / Revision of clinical case definitions: influenza-like illness and severe acute respiratory infection*. (<http://www.who.int/bulletin/volumes/96/2/17-194514/en/>). Accessed 2 July 2019.
20. **Sintonen H, National Centre for Health Program Evaluation (Australia)**. *The 15-D measure of health-related quality of life: reliability, validity and sensitivity of its health state descriptive system*. Fairfield, Vic.: National Centre for Health Program Evaluation, 1994.
21. **Rosenbaum PR, Rubin DB**. The central role of the propensity score in observational studies for causal effects. : 15.
22. **R Core Team**. *R: A Language and Environment for Statistical Computing*. Vienna, Austria: R Foundation for Statistical Computing, 2018.
23. **Tsuzuki S, Yoshihara K**. The characteristics of influenza-like illness management in Japan. *BMC public health* 2020; **20**: 568.
24. **Ministry of Education Culture Sports Science and Technology Japan**. School Health and Safety Act. 2015; Published online: 2015.
25. *UK guidelines for managing long-term effects of COVID-19 - The Lancet*. ([https://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(21\)00847-3/fulltext](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00847-3/fulltext)). Accessed 17 May 2021.
26. **Ayoubkhani D, et al**. Post-covid syndrome in individuals admitted to hospital with covid-19: retrospective cohort study. *BMJ British Medical Journal Publishing Group*, 2021; **372**: n693.
27. **Nalbandian A, et al**. Post-acute COVID-19 syndrome. *Nature Medicine* 2021; **27**: 601–615.
28. **Miyazato Y, et al**. Prolonged and Late-Onset Symptoms of Coronavirus Disease 2019. *Open forum infectious diseases* 2020; **7**: ofaa507.

343

344 **Table 1. Demographic characteristics of the participants**

	COVID-19 group	Other ILIs group
<b>Number of participants</b>	138	164
<b>Male</b>	97 (70.3)	110 (67.1)
<b>Age (median [IQR])</b>	45.5 [37.0, 55.0]	46.0 [36.0, 56.0]
<b>Number of household members</b>		
<b>1</b>	33 (23.9)	35 (21.3)
<b>2</b>	23 (16.7)	29 (17.7)
<b>3</b>	35 (25.4)	49 (29.9)
<b>&gt; 4</b>	47 (34.1)	51 (31.1)
<b>Diagnosis</b>		
<b>COVID-19</b>	138 (100.0)	0 (0.0)
<b>Seasonal influenza</b>	0 (0.0)	122 (74.4)
<b>RSV infection</b>	0 (0.0)	1 (0.6)
<b>Hand, foot, mouth disease</b>	0 (0.0)	1 (0.6)
<b>Pertussis</b>	0 (0.0)	1 (0.6)
<b>Common cold</b>	0 (0.0)	39 (23.8)
<b>Comorbidities</b>		

<b>Asthma</b>	37 (26.8)	30 (18.3)
<b>Allergic rhinorrhea</b>	46 (33.3)	45 (27.4)
<b>Atopic dermatitis</b>	25 (18.1)	20 (12.2)
<b>Neurological disorder</b>	11 (8.0)	3 (1.8)
<b>Respiratory diseases</b>	16 (11.6)	5 (3.0)
<b>Cardiovascular diseases</b>	17 (12.3)	7 (4.3)
<b>Diabetes mellitus</b>	23 (16.7)	8 (4.9)
<b>Renal diseases</b>	16 (11.6)	7 (4.3)
<b>Liver diseases</b>	10 (7.2)	8 (4.9)
<b>Metabolic diseases</b>	13 (9.4)	2 (1.2)
<b>Immunodeficiency</b>	14 (10.1)	4 (2.4)
<b>Pregnancy</b>	4 (2.9)	0 (0.0)
<b>No comorbidities</b>	58 (42.0)	72 (43.9)
<hr/>		
<b>Place of isolation</b>		
<b>Home</b>	86 (62.3)	157 (95.7)
<b>Hotel</b>	51 (37.0)	12 (7.3)
<b>Hospital</b>	51 (37.0)	7 (4.3)
<hr/>		
<b>Duration of work restriction</b>	14 [10, 23]	5 [4, 10]
<hr/>		

<b>Monthly wage (USD)</b>	2272.7 [1818.2, 4545.5]	2272.7 [1363.6, 3636.4]
<b>Proportion of wage covered during isolation</b>	80.0 [50.0, 100.0]	95.0 [50.0, 100.0]
<b>Education level</b>		
<b>Secondary school</b>	0 (0.0)	3 (1.8)
<b>High school</b>	22 (15.9)	42 (25.6)
<b>Vocational school</b>	29 (21.0)	15 (9.2)
<b>University</b>	71 (51.4)	91 (55.5)
<b>Graduate school</b>	16 (11.6)	13 (7.9)
<b>Quality of Life</b>	0.89 [0.73, 0.97]	0.95 [0.84, 0.99]
<b>Duration of isolation</b>	15.5 [11, 25]	7 [5, 12]
<b>Duration of symptoms</b>	17 [9, 32]	7 [4, 10]
<b>Ongoing symptoms</b>	11 (8.0)	1 (0.6)

345 ILI; influenza-like illness, RSV; respiratory syncytial virus, USD; United States Dollar

346 (110 Japanese Yen = 1 USD)

347 Numbers with brackets represent absolute number and percentage

348 Numbers with square brackets represent median value and interquartile range

349



350 **Table 2. Demographic characteristics of data after propensity score matching**

	COVID-19 group	Other ILIs group	SMD
<b>Number of participants</b>	128	128	
<b>Male</b>	92 (71.9)	89 (69.5)	0.052
<b>Age (median [IQR])</b>	44.0 [37.0, 54.0]	46.0 [36.0, 55.0]	0.019
<b>Diagnosis</b>			
<b>COVID-19</b>	128 (100.0)	0 (0.0)	
<b>Seasonal influenza</b>	0 (0.0)	94 (73.4)	
<b>RSV infection</b>	0 (0.0)	1 (0.8)	
<b>Hand, foot, mouth disease</b>	0 (0.0)	1 (0.8)	
<b>Pertussis</b>	0 (0.0)	1 (0.8)	
<b>Common cold</b>	0 (0.0)	31 (24.2)	
<b>Comorbidities</b>			
<b>Asthma</b>	36 (28.1)	24 (18.3)	
<b>Allergic rhinorrhea</b>	44 (34.4)	38 (29.7)	
<b>Atopic dermatitis</b>	25 (19.5)	15 (11.7)	
<b>Neurological disorder</b>	2 (1.6)	11 (8.6)	
<b>Respiratory diseases</b>	15 (11.7)	3 (2.3)	

<b>Cardiovascular diseases</b>	13 (10.2)	4 (3.1)	
<b>Diabetes mellitus</b>	22 (17.2)	5 (3.9)	
<b>Renal diseases</b>	15 (11.7)	4 (3.1)	
<b>Liver diseases</b>	9 (7.0)	6 (4.7)	
<b>Metabolic diseases</b>	12 (9.4)	2 (1.6)	
<b>Immunodeficiency</b>	13 (10.2)	2 (1.6)	
<b>Pregnancy</b>	3 (2.3)	0 (0.0)	
<b>No comorbidities</b>	53 (41.4)	55 (43.0)	0.0156
<b>Place of isolation</b>			
<b>Home</b>	79 (61.7)	123 (96.1)	
<b>Hotel</b>	48 (37.5)	11 (8.6)	
<b>Hospital</b>	47 (36.7)	74(3.1)	
<b>Education level</b>			0.019
<b>Secondary school</b>	0 (0.0)	0 (0.0)	
<b>High school</b>	27 (21.1)	21 (16.4)	
<b>Vocational school</b>	27 (21.1)	12 (9.4)	
<b>University</b>	66 (51.6)	80 (62.5)	
<b>Graduate school</b>	14 (10.9)	9 (7.0)	

351 ILI; influenza-like illness, SMD; standardized mean difference RSV; respiratory

352 syncytial virus, USD; United States Dollar (110 Japanese Yen = 1 USD)

353 Numbers with brackets represent absolute number and percentage

354 Numbers with square brackets represent median value and interquartile range

355

356

357 **Table 3. Comparison of outcomes between two groups by matched data**

	COVID-19 group	Other ILIs group	<i>p</i> value*
<b>Duration of symptoms</b>	18 [10, 33]	7 [4, 11]	< 0.001
<b>Duration of isolation</b>	16 [11, 25]	7 [5, 12]	< 0.001
<b>Productivity loss due to isolation (JPY)</b>	1424.3 [825.6, 2545.5]	606.1 [297.0, 1090.9]	< 0.001
<b>Quality of Life</b>	0.89 [0.72, 0.97]	0.96 [0.86, 0.99]	0.001

358 ILI; influenza-like illness, USD; United States Dollar, JPY; Japanese Yen (1 USD = 110

359 JPY)

360 \*Results of Mann-Whitney U test

361 Numbers with square brackets represent median value and interquartile range

362

363

364 **Figure 1. Probability density curve of duration of symptoms and isolation,**  
 365 **productivity loss and Quality of life**

366 Top left panel shows duration of symptoms. Top right panel shows duration of isolation.

367 Bottom left panel shows productivity loss. Bottom right panel shows Quality of life.

368 ILI; influenza-like illness, QOL; Quality of life

369 Red area represents COVID-19 group and Blue area represents other ILIs group.

370

